BrightSpec commercializes MRR, a novel spectroscopic technique that rapidly and definitively characterizes the unique three-dimensional structures of small molecules, including structural, spatial, and isotopic isomers. MRR leverages computational quantum chemistry to predict and validate structures without the need for reference standards. The company maintains an extensive database of calculated and validated structural spectra and offers tools for rapid identification of unknown compounds in crude samples. Its workflow enables high-throughput analysis without chromatography, providing quantitation directly from crude mixtures in minutes, and can be paired with software and minimal sample prep to deploy targeted instruments outside of analytical labs. BrightSpec reports customers across the pharmaceutical, consumer and beverage, and industrial chemical industries. The company intends to use the Series C proceeds to expand development efforts and broaden its business reach.

Total raised

$18M

Funding rounds

1

Latest round

Series C

Latest activity

Dec 2022